Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma

Medicine and Dentistry

• Oligoastrocytoma 100%
• Bevacizumab 100%
• Inpatient 100%
• Patient 30%
• Glioblastoma 20%
• Monotherapy 20%
• Survival 20%
• Biological Marker 10%
• Brain Tumor 10%
• Toxicity 10%
• Progression Free Survival 10%
• Hypertension 10%
• Adverse Event 10%
• Log Rank Test 10%
• Mucositis 10%
• Progressive Disease 10%
• Skin Infection 10%
• Antiangiogenic 10%
• Lipogenesis 10%
• Drug 10%
• Chemotherapeutic Agent 10%
• Fatigue 10%
• Eye Infection 10%
• Hand Foot Syndrome 10%
• Large Multicenter Trial 10%
• Fatty Acid Synthase 10%
• Dry Eye 10%
• Analysis 10%
• Therapeutic Procedure 10%
• Fatty Acid Synthase Inhibitor 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Bevacizumab 100%
• Astrocytoma 100%
• Monotherapy 20%
• Glioblastoma 20%
• Survival 20%
• Diseases 10%
• Biological Marker 10%
• Progression Free Survival 10%
• Hypertension 10%
• Adverse Event 10%
• Toxicity 10%
• Lipid 10%
• Mucosa Inflammation 10%
• Drug 10%
• Skin Infection 10%
• Hand Foot Syndrome 10%
• Brain Tumor 10%
• Fatty Acid Synthase 10%
• Fatigue 10%
• Fatty Acid Synthase Inhibitor 10%
• Dry Eye 10%
• Eye Infection 10%
• Dry Skin 10%